Catalog No.: PC-23458Not For Human Use, Lab Use Only.
CBS9106 (Felezonexor) is a reversible oral CRM1/exportin1 inhibitor, inhibits CRM1-dependent nuclear export, causing arrest of the cell cycle and inducing apoptosis in a broad spectrum of cancer cells.
CBS9106 (Felezonexor) is a reversible oral CRM1/exportin1 inhibitor, inhibits CRM1-dependent nuclear export, causing arrest of the cell cycle and inducing apoptosis in a broad spectrum of cancer cells. CBS9106 (Felezonexor) sensitize cells to radiation and to suppress the growth of a variety of cancer cell lines with IC50 values ranged from 22.3 or 35.6 nM in MM.1S or RPMI-8226 cells and from 3 to 278 nM in 60 other human cancer cell lines. CBS9106 (Felezonexor) inhibits HIV Rev function with IC50 of 5.5 nM. CBS9106 decreases CRM1 protein expression levels in MM.1S cells, inhibits NF-κB activity by protection against IκB-α degradation. CBS9106-mediated CRM1 depletion requires ubiquitin/proteasome pathway. CBS9106 directly binds to CRM1 in a competitive manner with Leptomycin B, binds Cys528 of CRM1 and the binding is reversible. CBS9106 (Felezonexor) significantly suppresses tumor growth and prolongs survival in human MM xenograft models.
